ERBB2 and breast carcinoma: In breast cancer, melittin suppressed the activation of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), two major drivers of tumor progression in HER2-enriched and triple-negative subtypes [18].